Skip to main content
Download PDF

Two-weeks repeated-dose oral toxicity study of Pediococcus acidilactici J9 in a mice model

BMC Microbiology volume 20, Article number: 372 (2020) Cite this article

Abstract

Background

Helicobacter pylori (H. pylori) is an important pathogen that causes chronic gastritis and peptic ulcer, and is related to the development of gastric carcinoma. Several chemicals, including antibiotics, have been used to eradicate H.pylori. However, more studies are yet requred to accomplish a sufficient therapy. Pediococcus acidilactici (P. acidilactici) J9 were studied for inhibition of binding of H.pylori binding to human gastric cell lines. This study was performed in order to investigate the repeated-dose toxicity of P. acidilactici J9 in male and female mice.

Results

C57BL/6 male and female Mus musculus were divided into four groups (n = 10 in each group). P. acidilactici J9 was administered daily by oral injection of vehicle control at dosage levels to a low-dose group (500 mg/kg/day), middle-dose group (1000 mg/kg/day), and high-dose group (2000 mg/kg/day) for 2 weeks. After 14 days of exposure, the blood biochemistry and hematology were investigated, along with a histopathology exam. There were no bacterial-related deaths or abnormal clinical signs in either gender of mouse. The data was observed during the period in terms of body weight, food intake, and water consumption. Also, no alterations in organ weights upon administration of P. acidilactici J9 alone were observed. The adhesion and growth of H. pylori were inhibited by a 24 h treatment of H. pylori and P. acidilactici J9 on adenocarcinoma gastric (AGS) cells, which are gastric cancer cells. Compared to the control group (AGS cell and H. pylori), the number of H. pylori analyzed by FACS significantly (p < 0.01) decreased after incubation of AGS cell with P. acidilactici J9 for 24 h.

Conclusions

These results suggest that the oral application of P. acidilactici J9, up to a dosage level of 2000 mg/kg/day, causes no adverse effects in both male and female mice. P. acidilactici J9 inhibits the adhesion of H.pylori to AGS cancer cells. When used as probiotics, P. acidilactici J9 may help decrease the occurrence of gastritis and reduce the risk of H.pylori infection with promising safety issues.

Background

Lactobacillus is a gram-positive microorganism that utilizes carbohydrates as the energy source and produces organic acids like lactic acid and acetic acid as final products. It is used industrially in various fermented products, like fermented vegetables and dairy products, which are broadly involved in the everyday life [1, 2]. Lactobacillus determines the flavor of fermented foods and the characteristics of fermented products, and it plays a critical role in the food preservation. This occurs by extending its shelf life via production of active antibiotic materials like organic acid and bacteriocin. Moreover, various function in the human body is also reported, such as the suppression of intestinal noxious bacteria, the decrease of blood cholesterol levels, anticancer effect, reinforcement of immune function, etc. Because of the Lactobacillus, as a probiotics, intakes living strain, it attracts attention as an antibacterial preparation that solves the residual tolerance problems, in addition to being recently utilized as a healthy functional food [3, 4].

Helicobacter pylori is a macroaerophilic gram-negative bacteria that causes chronic gastritis, peptic ulcer, and presumable gastric cancer. Accumulated evidence demonstrates that the eradication of these bacteria resolves H.pylori-associated disease [5]. Multicenter studies have shown that triple therapy via a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole (all taken twice daily). This therapy is among the most effective approaches to H. pylori eradication [6]. However, 5–10% of H. pylori strains are reportedly resistant to clarithromycin [7]. In addition, there was a study noted a clarithromycin-resistant mutation in 63% of H. pylori strains from patients in whom treatment with a regimen including clarithromycin was unsuccessful [8]. The treatment of H. pylori infection with antibiotics does not eradicate the organism and is also often accompanied by deleterious side effects [9]. Thus, although many experts believe that “untreatable” H. pylori is just ill-treated H. pylori, no clinical trial. To the best of our knowledge, H. pylori has not yielded a treatment that provides 100% eradication [10].

Recently, probiotic lactic acid bacteria (LAB) have been reported to control H. pylori. Also, several studies have examined the efficacy of various probiotic preparations for H. pylori eradication with and without co-interventions [11]. Moreover, a number of clinical trials have been undertaken to test the hypothesis that probiotic bacteria inhibits H. pylori infection [12]. Probiotics inhibit enteric pathogens such as Salmonella, Shigella, and Citrobacter rodentium in both in vitro and in vivo [13, 14], and potential clinical benefits in preventing or resolving gastrointestinal diseases have been demonstrated [15, 16]. These microorganisms provide gut protection through several mechanisms, including decreasing luminal pH by producing lactic acid [17, 18] and competing with gut pathogens for host surface receptors [19]. Nonetheless, it has been shown that probiotics may inhibit H. pylori growth, independent of pH and lactic acid levels [20].

We have focused on P. acidilactici J9, originated from Kimchi and Cheonguk-jang [21], which produces bacteriocin [22] that is known as a considerably widely used antibacterial agent. Recently, P. acidilactici J9 is attracting attention as probiotics because it has interesting properties, such as resistance to heat, cold, pH, and proteolytic treatments, which are the required properties for probiotics [23]. It is reported that P. acidilactici has the ability to survive through gastrointestinal tract passage, can survive from a drying process and during storage at 4°C for 60 days [24]. Moreover, P. acidilactici has been reported to have in vitro acvitity against H. pylori [25].

However, a systematic study on its repeated oral administration toxicity has not been reported yet. Therefore, we have investigated the toxicity of this new probiotics and its effect on the inhibition of growth of H. pylori. In vitro assays were carried out to determine whether the combination of P. acidilactici J9, and its adhesion to gastric cells thus impacting gastric acidity, inhibit the growth of H. pylori [26]. The current therapeutic regimen for H. pylori aims to eliminate bacterial growth with antibiotics and this reduces the total acidity of gastric acid.

In this study, repeated toxicity tests are performed as the stability test using mice of C57BL/6 type under the “standard of toxicity test for medicine and medical supplies (Korea food and drug administration notification No. 1999-61)”. We also demonstrated in in vitro models that P. acidilactici J9 in combination have beneficial effects similar to those of antibiotic therapy on H. pylori-infected gastric epithelium.

Results

Oral toxicity study of P. acidilactici J9 in a mice model: death rate and normal symptoms

P. acidilactici J9 was administrated by oral injection for 2 weeks and the Table 1 show the death rate and the normal symptoms of males and females observed for 2 weeks. During the experiment, experimental mice were observed at regular times, and no death was observed in the male and female administration group (Table 1). Also, during all of the experiment, in every administration group – low dose (500 mg/kg/day), medium dose (1000 mg/kg/day), and high dose (2000 mg/kg /day) - including the control group, no specific adverse symptoms are observed. In this study, a dose of 2000 mg/kg, which is a maximum dose of oral administration toxicity test, did not generate abnormal symptoms. It thus seems that the minimal lethal dose of this experimental materials exceeds 2000 mg/kg/day in both male and female.

Table 1 Mortality and clinical signs of male and female (mice) treated orally with P. acidilactici J9 for 14 days
Full size table

Oral toxicity study of P. acidilactici J9 in a mice model: changes in body weight

P. acidilactici J9 was orally administrated for 2 weeks with varying concentrations and the changes in body weight are shown in Table 2. Changes in body weight during the whole period of experiment were negligible for the control group, low dose group (500 mg/kg/day), medium dose group (1000 mg/kg/day), and high dose group (2000 mg/kg/day). Additionally, from the date of administration of experimental materials to the end of the experiment, there was a normal weekly increase in body weight in the control group and the administration group (Fig. 1a).

Table 2 Body weight changes of male and female (mice) treated orally with P. acidilactici J9 for 14 days
Full size table
Fig. 1
figure1

Changes in body weight and intake of C57BL/6 mice which treated P. acidilactici J9. Dosage is set by the standard of MFDS. Maximum dosage is set to 2000 mg/kg/day for both male and female, and with the geometric ratio of 1/2, low dose group, medium dose group, and high dose group are set by per body weight (kg) respectively. a For every animal, change of weight is measured just before the administration of test materials once a week at certain time during 2 weeks. b, c Intake of feeds and water is measured and calculated once a week. Feeds; solid feeds for laboratory animal are freely offered, and drinking water; filtration-purified water is also freely offered. N = 10 samples per group

Full size image

Oral toxicity study of P. acidilactici J9 in a mice model: intake of nutrition and water

There was no significant change in the control group and the experimental material administration group in the amount of intake of feed and water during the experiment period (Table 3). Although the water consumption was significantly reduced on day 14 when compared to day 7, since it was both seen in the control group and the administration group, so it could be regarded as the environmental effect, not an effect of administration. Therefore, it seems that the administration of experimental materials does not affect significantly the amount of intake of feed and water (Fig. 1b and c).

Table 3 Daily food and water consumption of male and female (mice) treated orally with P. acidilactici J9 for 14 days
Full size table

Oral toxicity study of P. acidilactici J9 in a mice model: necropsy results

As the result of the observation of main organs with naked eyes after the necropsy of experimental mice, there was no significant change in organs and specific necropsy opinion dependent on the dose of administration (Table 4). Some mice from female control group were excluded from the data due to black damaged areas of the spleen during organ harvest, which is just the characteristics of a mouse individual. However in both control group and administration group, blackish red discoloration at the spleen terminal, shrinkage of the right testicle, and thinning of the right atrium were observed. (CTR-F-001: discoloration of spleen; CTR-F-005: discoloration of spleen; 500 mg-F-001: discoloration of spleen; CTR-M-004: discoloration of spleen; CTR-M-005: thinning of right atrium; 500 mg-M-004: discoloration of spleen; 1000 mg-M-004: shrinkage of right testicle) However, as the same phenomenon was seen in the control group and the administration group, these are the characteristics of a mouse individual and is not an effect of administration.

Table 4 Gross findings of male and female (mice) treated orally with P. acidilactici J9 for 14 days
Full size table

Oral toxicity study of P. acidilactici J9 in a mice model: the weight of organs

The weight of organs were measured after repeated administration of P. acidilactici J9 which varied to low dose (500 mg/kg/day), medium dose (1000 mg/kg/day), and high dose (2000 mg/kg/day) for 2 weeks (Table 5). No changes were observed in the weight of brain, lung, testis, ovary, kidney, heart, spleen, and liver with respect to the administration of experimental materials and no abnormal changes were dependent on dose of administrations. Generally, when the toxic materials were ingested, liver takes the largest effect since the detoxification starts at the liver. However, there were no significant changes in each group on the observed weight of the liver. From the results above, the administration of P. acidilactici J9 does not affect the weight of organs.

Table 5 Organ weights of male and female (mice) treated orally with P. acidilactici J9 for 14 days
Full size table

Oral toxicity study of P. acidilactici J9 in a mice model: hematological tests

As the result of the measurement of hematological parameters, no significant changes were observed in control and administration groups (p ≤ 0.05) (Table 6). As a result of hematological examination, both the control group and the administration group were included in normal range and no dependence on dose was observed. This result is similar to the range previously reported in hematological fundamental database of which there is a repeated toxicity test for 2 weeks using mice.

Table 6 Hematology of male and female (mice) treated orally with P. acidilactici J9 for 14 days
Full size table

Oral toxicity study of P. acidilactici J9 in a mice model: blood biochemical analysis

As the result of the measurement of the indicator of blood biochemistry, no significant changes dependent on the administration of experimental materials were observed in the whole administration groups with respect to the control group. Both the control group and P. acidilactici J9 administration group showed normal parameters (p ≤ 0.05) (Table 7).

Table 7 Levels of serum biochemical indices of male and female (mice) treated orally with P. acidilactici J9 for 14 days
Full size table

Oral toxicity study of P. acidilactici J9 in a mice model: histopathology observations

For the histopathology test of P. acidilactici J9-administrated mice, liver and kidney were stained by hematoxylin and eosin. We have chosen to observe liver and kidney because those two are representative organs that react to toxicity [27]. As the result of the histopathology test, no lesions were observed in the liver, like infection, necrosis, iron pigmentation, and bilirubin pigmentation. The structure of liver cells were also normal (Fig. 2a). There was no lesions in the kidney, like infection and necrosis, and no changes were observed in kidney cells (Fig. 2b). Therefore, there is no significant changes in liver and kidney, and no extraordinary pathologic abnormality dependent on dose of experimental materials were observed in both the control group and administration group as the result of the histopathology test. This opinion seems to correspond with the long-term change of weight as well as the blood biochemical change. Mijung Lee had validated the histopathology findings.

Fig. 2
figure2

Histopathological examinations of the liver and Kidney. a, b Female and male C57BL / 6 mice were orally administered with P. acidilactici J9 for 14 days. The liver and kidneys of the control and P. acidilactici J9 administration animals were extracted and fixed with 10% neutral buffered formalin solution on the final necropsy day of all animals after gross lesion observation. Pathological lesions and structures such as liver, kidney infection, necrosis, and iron and bilirubin pigmentation were confirmed by H & E staining. Bar = 30 μm, N = 10 samples per group

Full size image

Inhibition of adhesion and growth of H.pylori in gastric epithelial cells in the presence of P. acidilactici J9

The adhesion and growth of H. pylori were inhibited by a 24 h treatment of H. pylori and P. acidilactici J9 on AGS cells, which are gastric cancer cells. Compared to the control group (AGS cell and H.pylori), the number of H. pylori analyzed by FACS significantly (p < 0.01) decreased after incubation of AGS cell with P. acidilactici J9 for 24 h. Control biological triplicate groups are also analyzed for statistical options (Fig. 3 and Figure S1 in Additional file 1).

Fig. 3
figure3

P. acidilactici J9 inhibits adhesion and growth of H. pylori in gastric epithelial cells. a After H. pylori supernatant and P. acidilactici J9 were treated for 24 h in AGS cells, H. pylori count was confirmed by flow cytometry. In the control group, the H.pylori number was confirmed by flow measurement after 24 h of treatment with H.pylori in the AGS cell. b H. pylori number was quantified by a flow cytometer. The experiment was repeated three times and the data are shown as the mean (SEM). **p < 0.01 versus control group

Full size image

Discussion

P. acidilactici J9 exerts as an antagonism against other enteric pathogens, primarily through the production of lactic acid and secretion of bacteriocin [28,29,30,31,32,33,34]. Thermo-stable bacteriocin is an antimicrobial peptide known to have a strong activity against food bacteria and pathogenic enteric bacteria [28, 35,36,37,38]. For these reasons, bacteriocin secreted by P. acidilactici J9 has a potential to inhibit other pathogenic bacteria, and probiotics including P. acidilactici J9 have potential to be used for commercial healthcare products like beverages and foods [21]. However, a systematic study on its repeated oral administration toxicity has not been reported yet.

Various antibiotics have been used for H.pylori eradication [39,40,41,42], since it is known to be an important causative agent of peptic ulcer, gastritis, gastric cancer, or mucosa associated lymphoid tissue lymphoma [43]. These antimicrobial agents have been pointed out for various problems such as adverse effects, risk of re-infection due to increased pH, appearance of resistant bacteria, and high cost [42, 44,45,46,47]. Recently, there is growing interest in probiotic lactic acid bacteria, which can play a role in the treatment of H.pylori by directly acting on H.pylori, with minimal clinical side effects of antibiotics [48,49,50,51,52].

This study investigated the toxicity and anti-H.pylori effect of P. acidilactici J9. Daily administration of P. acidilactici J9 in mice for 2 week showed no abnormal clinical signs in body weight, hematology, food intake and water consumption. In all test groups, no general symptoms and deaths from the test substance were observed. During the entire test period, body weight continuously increased but no significant change was observed with the control group. In addition, there were no significant differences in the gross observation, long-term weight change, hematology, blood biochemical and histopathologic examination of the organ in all the test substance administration groups, and all of them were within the normal range. As a result of repeated toxicity test for 2 weeks, P. acidilactici J9 was judged to be a safe and low-toxic substance. But further investigation will be needed to interpret the data that female mice at 1000 mg of dose showed higher heart, kidney (L, R) weight and lower thymus weight when compared to control, and that female mice at 500 and 2000 mg of dose showed lower kidney (L) weight when compared to control.

P. acidilactici J9, inhibits the adhesion of H.pylori to AGS gastric cancer cells. Probiotics refers to living microorganisms that are beneficial to the human body when consumed in moderate quantities [53, 54]. Most probiotics known to date are lactic acid bacteria [55, 56]. Probiotic bacteria such as lactic acid bacteria and beneficial bacteria survive in the stomach acid and bile acid in the body, reach the small intestine, multiply in the intestines and settle [57, 58]. It has a beneficial effect on health in the colon, and these probiotics should be non-toxic and non-pathogenic [59, 60]. Ingestion of probiotics not only helps maintain health, it also helps to improve various diseases such as infants, irritable bowel syndrome, and inflammatory bowel disease [61].

Based on our in vivo and in vitro results, when used as probiotics, P. acidilactici J9 may help decrease the occurrence of gastritis and reduce the risk of H.pylori infection with promising safety issues, without side effects.

Conclusions

In conclusion, we reported the toxicity and anti-H.pylori effect of P. acidilactici J9. Daily administration of P. acidilactici J9 in mice for 2 week showed no abnormal clinical signs in body weight, hematology, food intake and water consumption. Also, P. acidilactici J9, inhibited the adhesion of H.pylori to AGS gastric cancer cells. Based on our in vivo and in vitro results, when used as probiotics, P. acidilactici J9 might have the potential to decrease the occurrence of gastritis and the risk of H.pylori infection with promising safety issues, without side effects.

Methods

Model organisms and conditions

C57BL/6 mice of 4 weeks of age without certain pathogens are purchased from Orient Bio (Seongnam, Korea) at an amount of 20 males and females each. Normal and healthy mice without any weight loss are used in experiment by clinical observation during 7 days of education. Feeds are the following; solid feeds for laboratory animal are freely offered, and drinking water. The filtration-purified water is also freely offered to mice. The mice were house in groups with ad libitum access to food and water and a 12 h light / 12 h dark cycle. Also, P. acidilactici J9 has been prepared through Industry Promotion Administration.

Configuration of test group and set of dosage setting

Dosage was set by MFDS (Ministry of Food and Drug Safety) standards. Maximum dosage is set to 2000 mg/kg/day for both male and female, with the geometric ratio of 1/2, low dose group, medium dose group, and high dose group are set at 500, 1000, and 2000 mg per body weight (kg) respectively. 500, 1000, 2000 mg of dosage corresponds to 5 × 108 CFU, 1 × 109 CFU, and 2 × 109 CFU, however, we used the mg/ml unit which is more commonly used in the animal experiments. The number of mice in each group are set to 5 males and females each. Dosage is set to not exceed 0.2 ml per 10 g and calculated according to the body weight measured just before administration. Test materials are well-mixed to sterile distilled water before administration, and they are directly injected into the stomach by sonde for oral administration for once a day during 2 weeks. Sterile distilled water for injection is used as reference material.

Normal symptoms and observation of lethality in mice

Observation is conducted for 6 h after oral administration and starting from the next day, to observe change of general condition, as well as expression of addiction. This was held in presence of dead mice and symptoms that can be expressed by the test materials are observed carefully. In the case of abnormality, the type and the extent of symptoms are recorded individually. All mice were checked for death or critical condition.

Measurement of weight, feed and water intake

For every animal, change of weight is measured just before the administration of test materials once a week at a certain time during 2 weeks. Intake of feeds and water is measured and calculated weekly.

Necropsy and naked eye examination

Mice were anesthetized by CO2; the air atmosphere of chamber that contains mice was replaced to CO2 with the volume displacement rate of 20%/min, and all surgical procedures were performed under general anesthesia. Euthanasia of mice was done by collecting 0.5 ml – 0.8 ml of blood from the heart under anesthesia. The protocols were in accordance with official governmental guidelines, and all efforts were made to minimize the number of mice used and their suffering. Also, other organs was obtained by mice. The brain, kidney, liver, lung, reproductive organ, heart, spleen, and thymus are extracted and weighed. External findings such as abnormality of subcutaneous, internal organs and brain were observed with the naked eye.

Blood biochemical

The hematologic analysis of the serum is performed the same day of the necropsy, which is collected from a 3000 rpm, 20 min long, centrifugation of the blood and conducted by auto-analyzer (Hitachi-747, Hitachi Medical Co., Tokyo, Japan). Glucose; GLU, Blood Urea Nitrogen; BUN, Creatinine; CREA, Total cholesterol; T-CHOL, Albumin; ALB, Total Bilirubin; T-BIL, Alkaline Phosphatase; ALP, Aspartate Aminotransferase; AST (GOT), Alanine Aminotransferase; ALT (GPT), Triglyceride; TG, and Total protein; TP are measured.

Hematology

Mice were fasted for 8 h followed by the anesthetization before the necropsy. Part of the blood from the exsanguination is EDTA-treated and stored in tubes and then analyzed by blood auto-analyzer (System SE-9000, TOAMedical Electronics Co., Ltd., Kobe, Japan). Red blood cells, RBC, hematocrit, HCT, hemoglobin, Hb, mean corpuscular volume, MCV, mean corpuscular hemoglobin, MCH, mean corpuscular hemoglobin concentration, MCHC, white blood cells, WBC, Hemoglobin, HGB, Cellular Hb Concentration Mean, CHCM, Red Cell Distribution Width, RDW, Hb Distribution Width, HDW, Cellular Hb content, CH, Cellular Hb Distribution Width, CHDW, Platelet, PLT, Platelet Distribution Width, PDW, Plateletcrit, PCT, Neutrophil, NEUT, Neutrophil, NEUT%, Lymphocyte, LYMPH, Lymphocyte %, LYMPH%, Monocyte, MONO, Monocyte %, MONO%, Eosinophil, EOS, Eosinophil %, EOS%, Basophil, BASO, Basophil %, BASO%, Large Unstained Cells, LUC, Large Unstained Cells, LUC%, Reticulocyte Count, Retic#, Reticulocyte %, Retic%, Mean Corpuscular Volume of Retics, MCVr, Mean Corpuscular Volume of Retics %, MCVr%, Red Cell Distribution Width of Retics, RDWr*, Hb Distribution Width of Retics, HDWr*, Cellular Hb of Retics, CHr, and Cellular Hb Distribution Width of Retics, CHDWr* are measured.

Histopathology

Liver and kidney were extracted and fixed with a 10% neutral buffered formalin solution the day of final necropsy, after the observation of gross lesions on every animal which were administered with test materials. Then paraffin embedding wass conducted and hematoxylin & eosin dye performed with the sections of 3 ~ 4 um sections. Mijung Lee had validated the findings.

H. pylori preparation

H. pylori (ATCC 43504) used in this study were obtained and inoculated onto chocolate media, incubated for 5 ~ 7 days at 37 °C in a 10% CO2 incubator under aerobic conditions and then used for the examination. When the chocolate media is filled over 90%, H. pylori is swabbed with sterilized swabs and suspended in 20 ml of RPMI-1640 media to form the H. pylori suspension.

Cell culture

The human gastric adenocarcinoma cell lines AGS (KCLB 21739; Korea) cells were seeded at a density of 1 × 105 cells in 2 ml of RPMI-1640 (RPMI-1640; Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) and 1% penicillin-streptomycin (Invitrogen, USA) into 6 well culture plates (SPL) and cultured for 2 ~ 3 days at 37 °C in a 5% CO2 incubator.

Adhesion assay

When the AGS cell reach a density of 80% of the seeding plate, we eliminate the media from the plate and wash with phosphate buffered saline (PBS: Welgene, Daegu, Korea) 3 times. Experimental groups are as follows. For negative control, only AGS is seeded. For positive control, AGS is treated by 1 ml of H. pylori suspension. For the measurement of suppression of attachment, AGS is treated by 1 ml of H. pylori suspension (1 × 108 CFU/ml) and P. acidilactici J9 (1 × 108 CFU/ml) at a multiplicity of infection of 100. The culture plates seeded with AGS treated by H. pylori and P. acidilactici J9 are incubated for 90 min at 37 °C in a 5% CO2 incubator. The culture media is eliminated and the cells are carefully harvested. The cells are suspended in 500ul of PBS then examined with FACS.

Flow cytometry

The culture media is eliminated and the cells were washed and carefully harvested in PBS (phosphate buffered saline, WelGene, Daegu, Korea) using a cell scraper. Cells were counted and 1 × 106 cells were suspended in 1 ml cold PBS. Cells (5 × 106 or 1 × 107) were centrifuged at 1200 rpm for 5 min. The cells are suspended in 500ul of PBS then flow cytometric analysis was performed (FACS Calibur, BD Bioscience, CA, USA). The data were analyzed using Flowing Software (www.flowingsoftware.com).

Statistical analysis

All values shown in the figures are presented as mean ± standard error. A 2-tailed probability value below 0.05 was considered statistically significant. Data were analyzed using SPSS version 17.0 (SPSS Inc., USA).

Availability of data and materials

Data generated by and used in the study is available from the corresponding author upon reasonable request.

Abbreviations

P. acidilactici :

Pediococcus acidilactici

H. pylori :

Helicobacter pylori

AGS:

Adenocarcinoma gastric

LAB:

Lactic acid bacteria

RBC:

Red blood cells

HCT:

Hematocrit

Hb:

Hemoglobin

MCV:

Mean corpuscular volume

MCH:

Mean corpuscular hemoglobin

MCHC:

Mean corpuscular hemoglobin concentration

WBC:

White blood cells

HGB:

Hemoglobin

CHCM:

Cellular Hb Concentration Mean

RDW:

Red Cell Distribution Width

HDW:

Hb Distribution Width

CH:

Cellular Hb content

CHDW:

Cellular Hb Distribution Width

PLT:

Platelet

PDW:

Platelet Distribution Width

PCT:

Plateletcrit

NEUT:

Neutrophil

NEUT%:

Neutrophil %

LYMPH:

Lymphocyte

LYMPH%:

Lymphocyte %

MONO:

Monocyte

MONO%:

Monocyte %

EOS:

Eosinophil

EOS%:

Eosinophil %

BASO:

Basophil

BASO%:

Basophil %

LUC:

Large Unstained Cells

LUC%:

Large Unstained Cells

Retic#:

Reticulocyte Count

Retic%:

Reticulocyte %

MCVr:

Mean Corpuscular Volume of Retics

MCVr%:

Mean Corpuscular Volume of Retics %

RDWr*:

Red Cell Distribution Width of Retics

HDWr*:

Hb Distribution Width of Retics

CHr:

Cellular Hb of Retics

CHDWr*:

Cellular Hb Distribution Width of Retics

GLU:

Glucose

BUN:

Blood Urea Nitrogen

CREA:

Creatinine

T-CHOL:

Total cholesterol

ALB:

Albumin

T-BIL :

Total Bilirubin

ALP:

Alkaline Phosphatase

AST (GOT):

Aspartate Aminotransferase

ALT (GPT):

Alanine Aminotransferase

TG:

Triglyceride

TP:

Total protein

FACS:

Fluorescence-activated cell sorting

References

  1. 1.

    Cross ML, Ganner A, Teilab D, Fray LM. Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria. FEMS Immunol Med Microbiol. 2004;42(2):173–80. https://doi.org/10.1016/j.femsim.2004.04.001.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Jack RW, Tagg JR, Ray B. Bacteriocins of gram-positive bacteria. Microbiol Rev. 1995;59(2):171–200.

    CAS  Article  Google Scholar 

  3. 3.

    De Vuyst L, Leroy F. Bacteriocins from lactic acid bacteria: production, purification, and food applications. J Mol Microbiol Biotechnol. 2007;13(4):194–9. https://doi.org/10.1159/000104752.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Josson K, Scheirlinck T, Michiels F, Platteeuw C, Stanssens P, Joos H, et al. Characterization of a gram-positive broad-host-range plasmid isolated from Lactobacillus hilgardii. Plasmid. 1989;21(1):9–20.

    CAS  Article  Google Scholar 

  5. 5.

    Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994;89(8 Suppl):S116–28.

    CAS  PubMed  Google Scholar 

  6. 6.

    Lind T, Megraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication of helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999;116(2):248–53.

    CAS  Article  Google Scholar 

  7. 7.

    Maeda S, Yoshida H, Matsunaga H, Ogura K, Kawamata O, Shiratori Y, et al. Detection of clarithromycin-resistant helicobacter pylori strains by a preferential homoduplex formation assay. J Clin Microbiol. 2000;38(1):210–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Maeda S, Yoshida H, Ogura K, Kanai F, Shiratori Y, Omata M. Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Gut. 1998;43(3):317–21.

    CAS  Article  Google Scholar 

  9. 9.

    Aiba Y, Suzuki N, Kabir AM, Takagi A, Koga Y. Lactic acid-mediated suppression of helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol. 1998;93(11):2097–101. https://doi.org/10.1111/j.1572-0241.1998.00600.x.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change helicobacter pylori treatment: a matter of geography? World J Gastroenterol. 2013;19(45):8168–80. https://doi.org/10.3748/wjg.v19.i45.8168.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2009;21(1):45–53. https://doi.org/10.1097/MEG.0b013e32830d0eff.

    Article  PubMed  Google Scholar 

  12. 12.

    Hsieh PS, Tsai YC, Chen YC, Teh SF, Ou CM, King VA. Eradication of helicobacter pylori infection by the probiotic strains Lactobacillus johnsonii MH-68 and L. salivarius ssp. salicinius AP-32. Helicobacter. 2012;17(6):466–77. https://doi.org/10.1111/j.1523-5378.2012.00992.x.

    Article  PubMed  Google Scholar 

  13. 13.

    Johnson-Henry KC, Nadjafi M, Avitzur Y, Mitchell DJ, Ngan BY, Galindo-Mata E, et al. Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. J Infect Dis. 2005;191(12):2106–17. https://doi.org/10.1086/430318.

    Article  PubMed  Google Scholar 

  14. 14.

    Tien MT, Girardin SE, Regnault B, Le Bourhis L, Dillies MA, Coppee JY, et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol. 2006;176(2):1228–37.

    CAS  Article  Google Scholar 

  15. 15.

    Fernandez MF, Boris S, Barbes C. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol. 2003;94(3):449–55.

    CAS  Article  Google Scholar 

  16. 16.

    Lionetti E, Indrio F, Pavone L, Borrelli G, Cavallo L, Francavilla R. Role of probiotics in pediatric patients with helicobacter pylori infection: a comprehensive review of the literature. Helicobacter. 2010;15(2):79–87. https://doi.org/10.1111/j.1523-5378.2009.00743.x.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    De Keersmaecker SC, Verhoeven TL, Desair J, Marchal K, Vanderleyden J, Nagy I. Strong antimicrobial activity of Lactobacillus rhamnosus GG against Salmonella typhimurium is due to accumulation of lactic acid. FEMS Microbiol Lett. 2006;259(1):89–96. https://doi.org/10.1111/j.1574-6968.2006.00250.x.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol. 2005;21(1):44–50.

    PubMed  Google Scholar 

  19. 19.

    Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Phys. 1999;276(4 Pt 1):G941–50.

    CAS  Google Scholar 

  20. 20.

    Coconnier MH, Lievin V, Hemery E, Servin AL. Antagonistic activity against helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol. 1998;64(11):4573–80.

    CAS  Article  Google Scholar 

  21. 21.

    Hong S-J, Chong M-S, Ahn S-H. A review on effects of probiotics in atopic dermatitis. J Korean Med Ophthalmol Otolaryngol Dermatol. 2020;33(1):25–44. https://doi.org/10.6114/jkood.2020.33.1.025.

    Article  Google Scholar 

  22. 22.

    Bhunia AK, Johnson MC, Ray B. Purification, characterization and antimicrobial spectrum of a bacteriocin produced by Pediococcus acidilactici. J Appl Bacteriol. 1988;65(4):261–8. https://doi.org/10.1111/j.1365-2672.1988.tb01893.x.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Ribeiro MCO, Vandenberghe LPS, Spier MR, Paludo KS, Soccol CR, Soccol VT. Evaluation of probiotic properties of Pediococcus acidilactici B14 in association with Lactobacillus acidophilus ATCC 4356 for application in a soy based aerated symbiotic dessert. Braz Arch Biol Technol. 2014;57:755–65.

    Article  Google Scholar 

  24. 24.

    Barbosa J, Borges S, Teixeira P. Pediococcus acidilactici as a potential probiotic to be used in food industry. Int J Food Sci Technol. 2015;50(5):1151–7. https://doi.org/10.1111/ijfs.12768.

    CAS  Article  Google Scholar 

  25. 25.

    McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, Pérez-Aisa Á, Modolell I, et al. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: a randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23(5):e12529. https://doi.org/10.1111/hel.12529.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Zuo F, Appaswamy A, Gebremariam HG, Jonsson AB. Role of Sortase A in lactobacillus gasseri Kx110A1 adhesion to gastric epithelial cells and competitive exclusion of helicobacter pylori. Front Microbiol. 2019;10:2770. https://doi.org/10.3389/fmicb.2019.02770.

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Belhattab R, Merouani N. Acute toxicity of Aristolochia longa L. of aqueous extract in mice. J Drug Deliv Ther. 2020;10(3):4–10. https://doi.org/10.22270/jddt.v10i3.4055.

    CAS  Article  Google Scholar 

  28. 28.

    Anastasiadou S, Papagianni M, Filiousis G, Ambrosiadis I, Koidis P. Pediocin SA-1, an antimicrobial peptide from Pediococcus acidilactici NRRL B5627: Production conditions, purification and characterization. Bioresour Technol. 2008;99(13):5384–90. https://doi.org/10.1016/j.biortech.2007.11.015.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Stonsaovapak S, Kaneko J, Izaki K. Characterization of Bacteriocin Produced by Pediococcus acidilactici Isolated from Fermented Pork in Thailand. Agric Nat Resour. 1994;28(2):310–3.

    Google Scholar 

  30. 30.

    Bhunia AK, Johnson MC, Ray B, Kalchayanand N. Mode of action of pediocin AcH from Pediococcus acidilactici H on sensitive bacterial strains. J Appl Bacteriol. 1991;70(1):25–33. https://doi.org/10.1111/j.1365-2672.1991.tb03782.x.

    CAS  Article  Google Scholar 

  31. 31.

    Biswas SR, Ray P, Johnson MC, Ray B. Influence of growth conditions on the production of a Bacteriocin, Pediocin AcH, by Pediococcus acidilactici H. Appl Environ Microbiol. 1991;57(4):1265–7.

    CAS  Article  Google Scholar 

  32. 32.

    Bukhtiyarova M, Yang R, Ray B. Analysis of the pediocin AcH gene cluster from plasmid pSMB74 and its expression in a pediocin-negative Pediococcus acidilactici strain. Appl Environ Microbiol. 1994;60(9):3405.

    CAS  Article  Google Scholar 

  33. 33.

    Bauer R, Chikindas ML, Dicks LMT. Purification, partial amino acid sequence and mode of action of pediocin PD-1, a bacteriocin produced by Pediococcus damnosus NCFB 1832. Int J Food Microbiol. 2005;101(1):17–27. https://doi.org/10.1016/j.ijfoodmicro.2004.10.040.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Mehta R, Arya R, Goyal K, Singh M, K. Sharma A. Bio-preservative and therapeutic potential of Pediocin: recent trends and future perspectives. Recent Pat Biotechnol. 2013;7(3):172–8.

    CAS  Article  Google Scholar 

  35. 35.

    Mehta R, Arya R, Goyal K, Singh M, Sharma AK. Bio-preservative and therapeutic potential of pediocin: recent trends and future perspectives. Recent Pat Biotechnol. 2013;7(3):172–8.

    CAS  Article  Google Scholar 

  36. 36.

    Green G, Dicks LMT, Bruggeman G, Vandamme EJ, Chikindas ML. Pediocin PD-1, a bactericidal antimicrobial peptide from Pediococcus damnosus NCFB 1832. J Appl Microbiol. 1997;83(1):127–32. https://doi.org/10.1046/j.1365-2672.1997.00241.x.

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Oppegård C, Fimland G, Anonsen JH, Nissen-Meyer J. The Pediocin PA-1 accessory protein ensures correct disulfide bond formation in the antimicrobial peptide Pediocin PA-1. Biochemistry. 2015;54(19):2967–74. https://doi.org/10.1021/acs.biochem.5b00164.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Johnsen L, Fimland G, Eijsink V, Nissen-Meyer J. Engineering increased stability in the antimicrobial peptide Pediocin PA-1. Appl Environ Microbiol. 2000;66(11):4798–802. https://doi.org/10.1128/aem.66.11.4798-4802.2000.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Chiba N, Rao BV, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating helicobacter pylori. Am J Gastroenterol. 1992;87(12):1716–27.

    CAS  PubMed  Google Scholar 

  40. 40.

    Mégraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53(9):1374–84. https://doi.org/10.1136/gut.2003.022111.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19(4):409–14.

    PubMed  Google Scholar 

  42. 42.

    Alba C, Blanco A, Alarcón T. Antibiotic resistance in helicobacter pylori. Curr Opin Infect Dis. 2017;30(5):489–97. https://doi.org/10.1097/QCO.0000000000000396.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Sipponen P, Hyvarinen H. Role of helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol Suppl. 1993;196:3–6.

    CAS  Article  Google Scholar 

  44. 44.

    Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol. 2010;8(4):260–71. https://doi.org/10.1038/nrmicro2319.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Zullo A, De Francesco V, Bellesia A, Vassallo R, D'Angelo A, Scaccianoce G, et al. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice. J Gastrointestin Liver Dis. 2017;26(3):225–9. https://doi.org/10.15403/jgld.2014.1121.263.zul.

    Article  PubMed  Google Scholar 

  46. 46.

    Li H, Liang X, Chen Q, Zhang W, Lu H. Inappropriate treatment in helicobacter pylori eradication failure: a retrospective study. Scand J Gastroenterol. 2018;53(2):130–3. https://doi.org/10.1080/00365521.2017.1413132.

    Article  PubMed  Google Scholar 

  47. 47.

    Mohammadi M, Attaran B, Malekzadeh R, Graham DY. Furazolidone, an underutilized drug for H. pylori eradication: lessons from Iran. Dig Dis Sci. 2017;62(8):1890–6. https://doi.org/10.1007/s10620-017-4628-5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Kong YH, Zhang L, Yang ZY, Han C, Hu LH, Jiang HL, et al. Natural product juglone targets three key enzymes from helicobacter pylori: inhibition assay with crystal structure characterization. Acta Pharmacol Sin. 2008;29(7):870–6. https://doi.org/10.1111/j.1745-7254.2008.00808.x.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Wu L, Wang Z, Sun G, Peng L, Lu Z, Yan B, et al. Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. Sci Rep. 2019;9(1):12874. https://doi.org/10.1038/s41598-019-49415-3.

    Article  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Kafshdooz T, Akbarzadeh A, Majdi Seghinsara A, Pourhassan M, Nasrabadi HT, Milani M. Role of probiotics in managing of helicobacter pylori infection: a review. Drug Res. 2017;67(2):88–93. https://doi.org/10.1055/s-0042-116441.

    CAS  Article  Google Scholar 

  51. 51.

    Goderska K, Agudo Pena S, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol. 2018;102(1):1–7. https://doi.org/10.1007/s00253-017-8535-7.

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Eslami M, Yousefi B, Kokhaei P, Jazayeri Moghadas A, Sadighi Moghadam B, Arabkari V, et al. Are probiotics useful for therapy of Helicobacter pylori diseases? Comp Immunol Microbiol Infect Dis. 2019;64:99–108. https://doi.org/10.1016/j.cimid.2019.02.010.

    Article  PubMed  Google Scholar 

  53. 53.

    Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 2009;136(6):2015–31.

    CAS  Article  Google Scholar 

  54. 54.

    Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121(3):580–91.

    CAS  Article  Google Scholar 

  55. 55.

    Tannock GW. Probiotic properties of lactic-acid bacteria: plenty of scope for fundamental R & D. Trends Biotechnol. 1997;15(7):270–4.

    CAS  Article  Google Scholar 

  56. 56.

    Dickerson FB, Stallings C, Origoni A, Katsafanas E, Savage CL, Schweinfurth LA, et al. Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Prim Care Companion CNS Disord. 2014;16(1):PCC.13m01579. https://doi.org/10.4088/PCC.13m01579.

  57. 57.

    Cook MT, Tzortzis G, Charalampopoulos D, Khutoryanskiy VV. Microencapsulation of probiotics for gastrointestinal delivery. J Control Release. 2012;162(1):56–67. https://doi.org/10.1016/j.jconrel.2012.06.003.

    CAS  Article  PubMed  Google Scholar 

  58. 58.

    Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem. 2002;277(52):50959–65. https://doi.org/10.1074/jbc.M207050200.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Matsumoto M, Tsuji M, Sasaki H, Fujita K, Nomura R, Nakano K, et al. Cariogenicity of the probiotic bacterium lactobacillus salivarius in rats. Caries Res. 2005;39(6):479–83. https://doi.org/10.1159/000088183.

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Geier MS, Butler RN, Howarth GS. Probiotics, prebiotics and synbiotics: a role in chemoprevention for colorectal cancer? Cancer Biol Ther. 2006;5(10):1265–9.

    CAS  Article  Google Scholar 

  61. 61.

    Floch MH. Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr Treat Options Gastroenterol. 2003;6(4):283–8.

    Article  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge Financial assistance from the 0720142100 University Industrial Technology Force. We also express our appreciation to professor Nayoung Kim from Seoul National University Bundang Hospital for kindly providing H.pylori stock and the human gastric adenocarcinoma cell lines AGS (KCLB 21739; Korea) cells. We are also thankful to PDXen Biosystems Co. for offering technical assistant and idea.

Funding

This work was supported from the 0720142100 University Industrial Technology Force, and by 2018 research fund from 'The Korean Society of Ginseng'. The source of funding had no role in the study design, data collection, analysis, interpretation or writing of the manuscript.

Author information

Affiliations

  1. Department of Neurology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea

    Mijung Lee, Wooseok Im & Manho Kim

  2. Department of Veterinary Internal Medicine and Geriatrics, College of Veterinary Medicine, Kangwon National University, Gangwon-do, South Korea

    Jin-Young Chung

  3. Department of Psychology, Fordham University, New York, NY, USA

    Ka Yeun Kim

  4. Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, South Korea

    Wooseok Im & Manho Kim

  5. Protein Metabolism Medical Research Center, College of Medicine, Seoul National University Hospital, Seoul, South Korea

    Manho Kim

Authors
  1. Mijung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin-Young Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ka Yeun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wooseok Im
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ML performed experiments, analyzed data, wrote paper, JC provided advice in study design, critically discussed results, co-edited paper, KYK provided advice in study design, critically discussed results, co-edited paper, WI provided advice in study design, critically discussed results, co-edited paper, MK provided advice in study design, critically discussed results, co-edited paper. All authors have read and approved the manuscript.

Corresponding authors

Correspondence to Wooseok Im or Manho Kim.

Ethics declarations

Ethics approval and consent to participate

All experimental animal procedures performed were approved by the Institutional Animal Care and Use Committee (IACUC, Approval number: 16–0043-C2A1) of Seoul National University Hospital, which was accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Populations of H.pylori were analyzed with a flow cytometer. When the chocolate media was filled with over 90%, Helicobacter pylori was swabbed with sterilized swabs and suspended in RPMI-1640 media 20 ml to form Helicobacter pylori suspension. The population in a red gate were assayed as Helicobacter pylori.

Additional file 2.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lee, M., Chung, JY., Kim, K.Y. et al. Two-weeks repeated-dose oral toxicity study of Pediococcus acidilactici J9 in a mice model. BMC Microbiol 20, 372 (2020). https://doi.org/10.1186/s12866-020-02055-4

Download citation

Keywords

  • Pediococcus acidilactici J9
  • Repeated two-week oral dose toxicity
  • Mouse
  • Helicobacter pylori
  • AGS cell

BMC Microbiology

ISSN: 1471-2180

Contact us

\